Amplify Weight Loss Drug & Treatment ETF
THNR
4 hedge funds and large institutions have $919K invested in Amplify Weight Loss Drug & Treatment ETF in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
133% more capital invested
Capital invested by funds: $395K → $919K (+$524K)
100% more funds holding
Funds holding: 2 → 4 (+2)
8.16% more ownership
Funds ownership: 13.84% → 22% (+8.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$694K |
| 2 |
GS
GTS Securities
New York
|
+$249K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.92K |
| 4 |
GFA
Godfrey Financial Associates
Glenmont,
New York
|
+$51 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Cravens & Co Advisors
Cookeville,
Tennessee
|
-$390K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $670K | +$694K | +27,241 | New |
|
|
GS
2
GTS Securities
New York
| $240K | +$249K | +9,761 | New |
|
|
GFA
3
Godfrey Financial Associates
Glenmont,
New York
| $4.98K | +$51 | +2 | +1% |
|
|
4
UBS Group
Zurich,
Switzerland
| $4.75K | +$4.92K | +193 | New |
|
|
CCA
5
Cravens & Co Advisors
Cookeville,
Tennessee
| – | -$390K | -15,023 | Closed |
|
THNR Hedge Fund Activity: Q1 2026 in Review
4 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Amplify Weight Loss Drug & Treatment ETF (THNR) for Q1 2026, worth a combined $919K — up 133% from $395K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new THNR positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $694K. The largest seller was Cravens & Co Advisors, exiting entirely with an estimated $390K sold.
- 4 institutional investors held Amplify Weight Loss Drug & Treatment ETF (THNR) as of Q1 2026, up from 2 in Q4 2025.
- Funds reported $919K of Amplify Weight Loss Drug & Treatment ETF stock for Q1 2026, up 133% quarter-over-quarter.
- 3 funds opened new Amplify Weight Loss Drug & Treatment ETF positions in Q1 2026 and 1 closed out, a net change of +2 holders.
- The largest Amplify Weight Loss Drug & Treatment ETF buyer in Q1 2026 was Citadel Advisors, an estimated $694K added.
- The largest Amplify Weight Loss Drug & Treatment ETF seller in Q1 2026 was Cravens & Co Advisors, an estimated $390K sold.
Based on aggregated 13F filings for Q1 2026.